Telomerase

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Retrieved on: 
Wednesday, February 7, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, UTSW, Telomerase, SCLC, Interferon, Nature Communications, Clinical trial, Carcinoma, Diagnosis, Lung cancer, Orphan, Cancer, University

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications .

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications .
  • “This publication highlights a rather unique dual mechanism of action for THIO as a first-in-clinic telomere-targeted anticancer agent for potential treatment of SCLC,” said Sergei M. Gryaznov, PhD., MAIA’s Chief Scientific Officer.
  • Key findings in the published paper include:
    “With few, if any, effective treatments for small cell lung cancer, there is a widespread need for innovative therapeutic strategies.
  • The positive outcomes reported in our publication show THIO’s potential as a new therapeutic approach,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer.

Scientist Dr. Bill Andrews Joins Touchstone Essentials' Advisory Board

Retrieved on: 
Tuesday, January 30, 2024
Today (American TV program), Essential, Longevity, Telomerase, Health, Sierra Sciences, Management

RALEIGH, N.C., Jan. 30, 2024 /PRNewswire/ -- With over 50 patents and countless accomplishments in the biotech industry, Dr. Bill Andrews has made an indelible mark in the scientific community. Now, his expertise in the realm of anti-aging and longevity will be added to the scientific advisory board of Touchstone Essentials, a fast-growing e-commerce wellness company.

Key Points: 
  • Touchstone Essentials, a detox and wellness direct sales company, is marking the new year with an exciting addition to their scientific advisory board, leading longevity researcher, Dr. Bill Andrews Ph.D.
    RALEIGH, N.C., Jan. 30, 2024 /PRNewswire/ -- With over 50 patents and countless accomplishments in the biotech industry, Dr. Bill Andrews has made an indelible mark in the scientific community.
  • Now, his expertise in the realm of anti-aging and longevity will be added to the scientific advisory board of Touchstone Essentials, a fast-growing e-commerce wellness company.
  • Founder and CEO of Touchstone Essentials, Eddie Stone, is delighted to have Dr. Andrews join the team, "We are so excited for Dr. Andrews to share his years of expertise as part of our scientific advisory board, and believe we can accomplish great things together."
  • "I look forward to becoming an active and influential member of Touchstone Essentials' scientific advisory board.

Acquired Gene or Chromosome Alterations Clinical Pipeline Research Report 2023: Analysis of Stages of Development, Segments, Region and Countries, Regulatory Path and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 16, 2024
Genetics, Health, Clinical Trials, Gene, Genetic testing, One-two, Clinical trial, Telomerase, BRCA, Vaccine

The "Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • Acquired Gene or Chromosome Alterations Pipeline Report provides comprehensive information about the Acquired Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • This report offers extensive coverage of Acquired Gene or Chromosome Alterations under development, providing comprehensive insights into pipeline products, major players, developmental activities, clinical trial data, and recent developments in the segment/industry.
  • It also lists all the pipeline projects involving major players engaged in the development of Acquired Gene or Chromosome Alterations.

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer

Retrieved on: 
Monday, September 11, 2023
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Baxalta, CRISPR, Employment, Momenta, Telomerase, Finance, History, Editas Medicine, Baxter International, Genzyme, Imetelstat, Bentley University, Retirement, Corporation, Acquisition, Geron Corporation, Risk, Syndrome, CFO, Johnson & Johnson, Commercial, Treasurer, Genome, Management, Sanofi, Accounting

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023.
  • Ms. Robertson's appointment follows the retirement of Olivia Bloom, Geron's incumbent CFO, also effective September 25, 2023.
  • Olivia’s strategic vision, financial prowess and inspiring dedication have been foundational in making Geron what we are today,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.
  • “In the same breath, I am also thrilled to welcome Michelle Robertson to the Geron executive management team at this important moment in our history.

Rejuvenation Technologies Raises $10.6M Seed Financing Led by Khosla Ventures to Develop mRNA Therapeutics to Reverse Aging

Retrieved on: 
Wednesday, September 6, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Nobel Prize, DNA, Human, Partnership, Cell death, Telomerase, Telomere, Stanford University, Ageing, Multimedia, COVID, Cell, RNA, The FASEB Journal, Messenger, Lung, Pulmonary fibrosis, Cellular senescence, Notifiable disease, University, Khosla Ventures, Y Combinator, Immune system, Chief medical informatics officer, Mouse, Liver, LNP, University of Queensland, Cirrhosis, Company of Merchant Adventurers of London, B cell, Liver failure, IND, Rejuvenation, Pharmaceutical industry, Vaccine

Rejuvenation Technologies , a biotechnology company developing mRNA-based therapeutics to address mechanisms of aging, today announced a $10.6M seed financing round led by Khosla Ventures.

Key Points: 
  • Rejuvenation Technologies , a biotechnology company developing mRNA-based therapeutics to address mechanisms of aging, today announced a $10.6M seed financing round led by Khosla Ventures.
  • Shanda Ventures, Asymmetry Ventures, Merchant Adventures, Longevity Tech Fund, and Y Combinator also participated in the round.
  • View the full release here: https://www.businesswire.com/news/home/20230906481334/en/
    From left to right, Rejuvenation Technologies Founders Glenn Markov, COO, John Ramunas, CEO.
  • We are excited to continue working together as Rejuvenation advances its technology platform, partnership discussions, and internal pipeline towards clinical trials.”

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS

Retrieved on: 
Monday, August 21, 2023
Research, Hospitals, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Telomerase, New Drug Application, NDA, Cancer, MDS, Imetelstat, Corporation, Geron Corporation, Patient, Risk, Transfusion-dependent anemia, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron’s New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron’s New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).
  • “The FDA’s acceptance of our New Drug Application is an important landmark along our steadfast journey to bring telomerase inhibition with imetelstat to the market,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.
  • Statistically significant and clinically meaningful efficacy results were achieved across key MDS subgroups irrespective of ring sideroblast (RS) status, baseline transfusion burden and IPSS risk category.
  • Additionally, Geron expects to submit a Marketing Authorization Application (MAA) in the European Union (EU) in the fourth quarter of 2023.

Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat

Retrieved on: 
Tuesday, June 20, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MDS, New Drug Application, Imetelstat, NDA, Corporation, Geron Corporation, Telomerase, Patient, Risk, Transfusion-dependent anemia, TI, Pharmaceutical industry

“This pioneering achievement to submit the first New Drug Application to the FDA for a telomerase inhibitor reflects the dedication, commitment and teamwork of so many people who believed targeting telomerase could make a significant difference for patients,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.

Key Points: 
  • “This pioneering achievement to submit the first New Drug Application to the FDA for a telomerase inhibitor reflects the dedication, commitment and teamwork of so many people who believed targeting telomerase could make a significant difference for patients,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
  • As allowed under imetelstat’s Fast Track designation in lower risk MDS, Geron has requested that the FDA grant Priority Review of the NDA.
  • Under standard practice, Geron expects FDA communication in 60 days whether the NDA was accepted for review and the timeline of such review (i.e., priority or standard).
  • Additionally, based on IMerge Phase 3, Geron expects to submit a Marketing Authorization Application (MAA) in the EU in the second half of 2023.

Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Retrieved on: 
Tuesday, June 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Telomerase, Majesty of the Seas, Clinical trial, Acute myeloid leukemia, MDS, Imetelstat, AML, Publication, Corporation, Geron Corporation, Patient, Risk, Therapy, AM, Principal, IMPRESS, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Company’s first-in-class telomerase inhibitor, in patients with acute myeloid leukemia (AM)L, or higher risk myelodysplastic syndromes (MDS), who are relapsed/refractory/intolerant to hypomethylating agents (HMAs).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Company’s first-in-class telomerase inhibitor, in patients with acute myeloid leukemia (AM)L, or higher risk myelodysplastic syndromes (MDS), who are relapsed/refractory/intolerant to hypomethylating agents (HMAs).
  • “This trial is based on multiple preclinical publications that describe the role of telomerase in AML, which have reported that inhibiting telomerase in both mouse and human AML models targets and potentially depletes leukemic stem cells and impairs their leukemic progression,” said Faye Feller, M.D., Executive Vice President, Chief Medical Officer of Geron.
  • “We are delighted that the first patient has been dosed in the investigator-led IMpress Phase 2 study, an important first step to understanding the potential impact of imetelstat in relapsed/refractory AML and higher risk MDS.”
    “Despite some recent advances in the treatment of AML and higher risk MDS, there is still a tremendous unmet need for new agents, especially in the relapsed/refractory setting,” said Uwe Platzbecker, M.D., Department of Hematology, Cellular Therapy and Hemostaseology, Leipzig University Hospital, Leipzig, Germany, and Principal Investigator of IMpress.
  • “With the first patient dosed and several in screening, we are pleased that IMpress Phase 2 is underway and look forward to understanding more about the potential efficacy of imetelstat in this rather frail and elderly patient population.”

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
Monday, June 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones

Retrieved on: 
Thursday, March 16, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Mutation, Lineage Cell Therapeutics, Imetelstat, ESA, Webcast, Fast Track, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, HMA, Exercise, Survival, Depreciation, OS, MDS, PRO, Acute myeloid leukemia, MAA, Patient, Reverse transcriptase, Anemia, Corporation, Asterias, FDA, GAAP, Cytogenetics, Bone marrow, MD Anderson Cancer Center, Geron Corporation, IMPRESS, Safety, Clinical trial, Telomerase, AML, Food, Intellectual property, NDA, MF, Pharmaceutical industry, Vaccine, Risk management, Cryptocurrency, EU

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2022.
  • In addition, the Company received $59.8 million upon the cash exercise of outstanding warrants in January and February 2023.
  • For the fourth quarter of 2022, the Company reported a net loss of $42.6 million, or $0.10 per share, compared to $32.0 million, or $0.10 per share, for the fourth quarter of 2021.
  • ET on Thursday, March 16, 2023 to discuss business updates, expected upcoming milestones and fourth quarter and full year 2022 financial results.